At present, while genomic and phenotypic indicators of chromosomal instability have been recognized to differentiate patients who could potentially gain from STING inhibition or activation, it is suggested that additional research and pre-clinical trials should be conducted to clarify the utility of STING agonists or antagonists across different tumor types or stages [75]. This evidence concerns the gene STING1 and neoplasm.